Volume 10 Supplement 1

First European Congress on Hereditary ATTR amyloidosis

Meeting abstracts

Publication of this supplement was funded by the First European Congress on Hereditary ATTR amyloidosis.

First European Congress on Hereditary ATTR amyloidosis.

Paris, France2-3 November 2015

Concatenated PDF 10S1

Content type: Invited speaker presentation

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP

Authors: Nadine Attal

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I1

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Neuropathic phenotypes and natural history of FAP

Authors: David Adams

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I2

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Which assessment for the carriers: the cardiac view

Authors: Arnt V Kristen

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I3

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

When to decide to enroll a TTR-FAP patient in a Clinical Trial?

Authors: Juan Buades

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I4

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Preimplantation genetic diagnosis for TTR-FAP in Portugal

Authors: Filipa Carvalho

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I5

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

TTR-FAP: liver transplant vs oral medication. How and when

Authors: Teresa Coelho

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I6

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Which assessment for the carriers ? The point of view of the neurologist

Authors: Isabel Conceicão

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I7

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

ATTR-FAP: liver transplantation vs oral medication, how and when

Authors: Bo Goran Erikzon

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I8

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)

Authors: Natália Ferreira

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I9

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Imaging cardiac ATTR amyloid

Authors: Philip N Hawkins

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I10

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Minimal assessment of index cases: the point of view of the neurologist

Authors: Ernst Hund

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I11

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis

Authors: Luisa Lobato

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I12

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Do we need to demonstrate Amyloid in tissue?

Authors: Laurent Magy

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I13

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Emerging CNS involvement in FAP-TTR long survival patients

Authors: Luisa Maia

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I14

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Biopsy experience in a FAP endemic area

Authors: Manuel Melo Pires

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I15

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

New tools to diagnose and follow FAC patients: biomarkers

Authors: Giampaolo Merlini

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I16

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

New therapeutic perspectives – amyloid removal

Authors: Mark Pepys

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I17

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Cardiologic Phenotypes and Natural History of FAC

Authors: Claudio Rapezzi

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I18

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

TTR amyloidosis: a scientific journey since Andrade

Authors: Maria João Saraiva

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I19

Published on: 2 November 2015
- View Full Text
- View PDF
Content type: Invited speaker presentation

Guidelines for genetic counselling in ATTR amyloidosis

Authors: Jorge Sequeiros

Citation: Orphanet Journal of Rare Diseases 2015 10(Suppl 1):I20

Published on: 2 November 2015
- View Full Text
- View PDF

Orphanet Journal of Rare Diseases

First European Congress on Hereditary ATTR amyloidosis

Meeting abstracts

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP

Neuropathic phenotypes and natural history of FAP

Which assessment for the carriers: the cardiac view

When to decide to enroll a TTR-FAP patient in a Clinical Trial?

Preimplantation genetic diagnosis for TTR-FAP in Portugal

TTR-FAP: liver transplant vs oral medication. How and when

Which assessment for the carriers ? The point of view of the neurologist

ATTR-FAP: liver transplantation vs oral medication, how and when

Ophtalmologic changes in transthyretin familial amyloid polyneuropathy (ATTR-FAP)

Imaging cardiac ATTR amyloid

Minimal assessment of index cases: the point of view of the neurologist

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis

Do we need to demonstrate Amyloid in tissue?

Emerging CNS involvement in FAP-TTR long survival patients

Biopsy experience in a FAP endemic area

New tools to diagnose and follow FAC patients: biomarkers

New therapeutic perspectives – amyloid removal

Cardiologic Phenotypes and Natural History of FAC

TTR amyloidosis: a scientific journey since Andrade

Guidelines for genetic counselling in ATTR amyloidosis

Follow

Orphanet Journal of Rare Diseases

Contact us